Here's a number that should get every parent's attention: 615,000 vaccinated men versus 2.3 million unvaccinated. That's the scale of the largest study ever conducted on HPV vaccination in males, and the results are unequivocal - the vaccine protects men from cancer.
The research, published in JAMA Oncology, found that vaccinated men had a significantly lower risk of HPV-related cancers compared to their unvaccinated peers. We're talking about head and neck cancers, oesophageal cancer, anal cancer, and penile cancer - all of which can be caused by human papillomavirus infection.
For years, HPV vaccination has been primarily marketed as protection for girls against cervical cancer. And it works brilliantly for that. But HPV doesn't discriminate by sex - it infects anyone, and it can cause cancer in anyone.
The sheer size of this study matters. With nearly 3 million participants, this isn't a preliminary finding that might not hold up. This is robust evidence from a real-world population.
Here's what makes this particularly compelling: head and neck cancers caused by HPV have been rising in men for decades, even as cervical cancer rates have fallen in vaccinated populations. We've known the virus was the culprit, but now we have clear evidence that the vaccine works as prevention in males too.
The study adds to a growing body of evidence supporting universal HPV vaccination regardless of sex. Several countries, including the United Kingdom and Australia, already offer the vaccine to all adolescents. Others vaccinate only girls, despite the fact that HPV-related cancers affect both sexes.
The universe doesn't care what we believe. Let's find out what's actually true. And what's true is that this vaccine prevents cancer in men. The numbers are compelling enough that the conversation should shift from "should we vaccinate boys?" to "why aren't we vaccinating all boys?"
